AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03883360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Description: Participants receive a single dose of CBD (600 mg p.o.) per day for 12 weeks.
Study NCT03883360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive a single daily dose of the oil vehicle used to dissolve CBD but without any active ingredient, in the same amount as the CBD group, for 12 weeks.
Study NCT05297201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL500036 - low dose
Description: CPL500036 will be given orally. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily.
Study NCT05297201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPL500036 - high dose
Description: CPL500036 will be given orally. Each patient is to take 4 capsules with active substance daily.
Study NCT05297201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given orally. Each patient is to take 4 capsules of placebo daily.
Study NCT06660225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Percept Deep Brain Stimulation Therapy [Sham Control Stimulation]
Description: Deep brain stimulation is a surgery where bilateral electrodes are precisely inserted to specific brain targets affected by a disease state, and electrical stimulation is applied to achieve symptom relief. DBS is a reversible and adjustable treatment option and is now a preferred alternative to neurosurgical ablation. Sham Stimulation=DBS OFF
Study NCT06556355 — intervention group
Intervention type: OTHER
Intervention: neoadjuvant chemoradiation and McKeown esophagectomy
Description: Treatment protocol:~1. All patients were irradiated a total prescribed dose of 40-50.4 Gy in 20-28 fractions by a 6-8 MV photons linear accelerator with the intensity-modulated radiotherapy or volumetric modulated arc therapy technique.~2. Concurrent chemotherapy was cisplatin-based.~3. McKeown esophagectomy (three incision) consisted of thoracic esophageal mobilization with lymphadenectomy, abdominal exploration and stomach mobilization with lymphadenectomy, and subsequently left cervical incision for anastomosis. The lymphadenectomy was total two-field (thoracic + abdomen).
Study NCT06660225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Percept Deep Brain Stimulation Therapy [Therapeutic stimulation]
Description: Deep brain stimulation is a surgery where bilateral electrodes are precisely inserted to specific brain targets affected by a disease state, and electrical stimulation is applied to achieve symptom relief. DBS is a reversible and adjustable treatment option and is now a preferred alternative to neurosurgical ablation. Therapeutic Stimulation= DBS ON
Study NCT06625762 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nantes bariatric surgery cohort
Description: The participants will be individuals living with obesity undergoing bariatric surgery
Study NCT06630741 — intervention group
Intervention type: OTHER
Intervention: alternative midwifery units (AMU)
Description: Alternative midwifery birth units are a new model of care in France in which the midwife is the primary health care professional caring for low-risk pregnant women, as opposed to those cared for by an obstetrician-led medical team. Accordingly, alternative midwifery birth units also provide a space within which midwives can practice to their fullest potential with more professional autonomy than in a traditional obstetric setting. These birth units emphasizes care that promotes normal physiologic pregnancy and labor and supports the natural ability of women to experience birth with minimum or no routine intervention.~Alternative midwifery birth units named Filière physiologique co-exist in the same building on the same site as a hospital or host obstetric unit. In the event a laboring women needs comprehensive emergency obstetric care, she can be transferred immediatly in a conventionnal birth room
Study NCT06631261 — intervention group
Intervention type: OTHER
Intervention: No intervention; Observational study
Description: No intervention
Study NCT06704633 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sacubitril / Valsartan Oral Tablet
Description: A 36-hour wash-out of ACE inhibitors before initiating ARNI will be done, because of a risk of angioedema if ARNI is started without a wash-out period. The ACE inhibitor or ARB will be switched to sacubitril/valsartan 50mg twice daily (24.3 mg sacubitril, 25.7mg valsartan) for two weeks, increased to 100mg twice daily for three weeks, followed by 200mg twice daily
Study NCT06706518 — intervention group
Intervention type: PROCEDURE
Intervention: Single-shot ablation technologies
Description: Comparison of fluoroscopy time and dose-area product (DAP) between different single-shot ablation technologies.~* PolarFit balloon catheter with adjustable diameter 28 to 31 mm. This catheter will be used in patients with persistent AF and dilated left atrium, where the ability to encompass more of the atrial myocardium at the level of the antrum of the pulmonary veins allows a greater number of potential AF perpetuating regions to be covered.~* ArcticFront Advance Pro 28 mm diameter balloon catheter\*.~* 28 mm diameter PolarX balloon catheter\*.
Study NCT05183984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy (carboplatin + paclitaxel) will be administred by intravenous infusion, AUC 5-6 q3w - 5 cycles during the treatment period
Study NCT05183984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-Awwb
Description: MVASI (bevacizumab biosimilar) will be administrated by intravenous infusion at the second chemotherapy cycle for 5 cycles.~the administration will continue during maintenance phase. Total bevacizumab duration therapy is 15 months.
Study NCT05183984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: niraparib will be administered orally once daily continuously after chemotherapy (+/- bevacizumab) cycles (maintenance treatment period). Total niraparib duration mainance treatment period is 2 years.
Study NCT06714149 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Immunoreactivity testing
Description: Blood samples will be collected and used to determine the intensity of the allergenicity of the subject toward different types of pollen. This will be done by the detection of sIgE antibodies to the pollen extracts and basophil activation testing (BAT) with pollen extracts.
Study NCT06714149 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Immunoreactivity testing (negative control)
Description: Blood samples will be collected and used to determine the background activity of our immunoreactivity tests. The investigators will use samples from negative controls to demonstrate that non-allergic individuals do not react to our assays, confirming that our pollen extracts have no background reactivity. This will be done by the detection of sIgE antibodies to the pollen extracts and basophil activation testing (BAT) with pollen extracts.
Study NCT06711783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family based therapy
Description: Family based therapy following the Maudsley model
Study NCT06714227 — intervention group
Intervention type: GENETIC
Intervention: Molecular analysis of genomic DNA (exome sequencing) from peripheral blood sample
Description: The first level of investigation will focus on genes already described in cases of pathogenic germline variants of prostate cancer and/or DNA repair system genes. The second level of investigation will consider variants in genes known to confer increased risk of cancer development, e.g., genes listed in the UK health system's solid tumor predisposition gene panel. Finally, pathogenic/probably pathogenic variants in the exome in genes attributable to increased risk will be evaluated on the basis of molecular pathway and findings in the scientific literature.
Study NCT06713473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehumanized Intervention
Description: Participants will:~1. be provided with a lay summary of an ostensible research article that used quantitative and qualitative data to capture the experiences of feeling less than human and mechanisms for reclaiming human identity. The summary will reveal general themes of humanness based on participant responses including body and soul awareness, agency, connection, and creativity.~1. write a 30-minute reflective essay on how did the rehumanization efforts described in the survey make people feel more human? where they will be encouraged to use examples from their own lives~2. asked to create videos based on the insights shared in the essays. The researchers will explain, We would like to record you reading your essay on camera. We believe it would be especially impactful for clinicians developing these interventions to hear directly from someone who has recently navigated similar experiences.
Study NCT06713473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: Participants will:~1. be provided with a lay summary of an ostensible research article that used quantitative and qualitative data to capture the experiences of political attitudes and routes to political sophistication. The summary will reveal general themes of political sophistication based on participant responses including gathering information through diverse news outlets, analyzing policy and legislation, and participation in civic engagement~1. write a 30-minute reflective essay on how did the political efforts described in the survey refine political attitudes? where they will be encouraged to use examples from their own lives~2. asked to create videos based on the insights shared in the essays. The researchers will explain, We plan to take excerpts of what you write here and share it with future voters to aid in developing political attitudes.
Study NCT06713473 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Interview
Description: Self-Injurious Thoughts and Behaviors Interview-Short Form (SITBI-SF). Participants will complete an in-person interview featuring 72-items about their history of self-injury and suicidal behaviors. This interview includes 6 yes/no style questions about suicidal thoughts, suicidal plans, suicidal gestures, suicidal attempts, nonsuicidal self-injury thoughts, and nonsuicidal self-injury. Each category that is endorsed, across the lifetime, has follow up questions surrounding times, duration, intensity, severity, type, and if medical attention was sought. This interview has sound psychometric properties.
Study NCT06713473 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinical Interview
Description: Self-Injurious Thoughts and Behaviors Interview-Short Form (SITBI-SF). Participants will complete an in-person interview featuring 72-items about their history of self-injury and suicidal behaviors. This interview includes 6 yes/no style questions about suicidal thoughts, suicidal plans, suicidal gestures, suicidal attempts, nonsuicidal self-injury thoughts, and nonsuicidal self-injury. Each category that is endorsed, across the lifetime, has follow up questions surrounding times, duration, intensity, severity, type, and if medical attention was sought. This interview has sound psychometric properties.
Study NCT06713473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Report Measures
Description: Depressive Symptom Index - Suicidality Subscale (DSI-SS). Patient Health Questionnaire-8 (PHQ-8). Interpersonal Needs Questionnaire (INQ). Self-Dehumanization Scale (SDS).
Study NCT06713473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Report Measures
Description: Depressive Symptom Index - Suicidality Subscale (DSI-SS). Patient Health Questionnaire-8 (PHQ-8). Interpersonal Needs Questionnaire (INQ). Self-Dehumanization Scale (SDS).
Study NCT06713473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Draw
Description: Five milliliters of blood will be drawn before and after study interventions for the quantification of plasma oxytocin concentrations by certified phlebotomists. Samples will be collected into chilled EDTA tubes, inverted ten times to mix with anticoagulants, and centrifuged at 1600g for 15 minutes at 4˚C. Cleared plasma will be aliquoted into cryotubes and stored at -80˚C. Consistent with expert recommendations, oxytocin levels will be obtained from the samples diluted 1:4 (i.e., oxytocin can be discarded through plasma proteins when incorporating an extraction step before conducting the enzyme-linked immunosorbent assay \[ELISA\]). Second, to buffer against contrasting concerns, an aliquot of each sample will be analyzed for test-retest purposes. Oxytocin concentrations will be measured using a validated commercially available and sensitive ELISA neurophysin kit (Abcam).
Study NCT06713473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Five milliliters of blood will be drawn before and after study interventions for the quantification of plasma oxytocin concentrations by certified phlebotomists. Samples will be collected into chilled EDTA tubes, inverted ten times to mix with anticoagulants, and centrifuged at 1600g for 15 minutes at 4˚C. Cleared plasma will be aliquoted into cryotubes and stored at -80˚C. Consistent with expert recommendations, oxytocin levels will be obtained from the samples diluted 1:4 (i.e., oxytocin can be discarded through plasma proteins when incorporating an extraction step before conducting the enzyme-linked immunosorbent assay \[ELISA\]). Second, to buffer against contrasting concerns, an aliquot of each sample will be analyzed for test-retest purposes. Oxytocin concentrations will be measured using a validated commercially available and sensitive ELISA neurophysin kit (Abcam).
Study NCT06714669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Control Group (Propofol Anesthesia Arm):~Patients in this arm will receive Propofol as the primary anesthetic agent for general anesthesia. Propofol is a well-established anesthetic drug commonly used in clinical practice for its rapid onset and short duration of action. Similar to the experimental group, the dosing regimen and administration protocol for Propofol will be tailored to the individual patient's needs and the surgical procedure. Hemodynamic stability and other vital signs will also be closely monitored in this group to assess the safety and effectiveness of Propofol in comparison to Remimazolam.
Study NCT06714669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Experimental Group (Remimazolam Anesthesia Arm):~Patients in this arm will receive Remimazolam as the primary anesthetic agent for inducing and maintaining general anesthesia. Remimazolam belongs to a new class of benzodiazepines and acts by enhancing the activity of GABAA receptors, leading to sedation and anesthesia. The specific dosing regimen and administration protocol for Remimazolam will be determined based on the patient's characteristics and the surgical procedure being performed. Close monitoring of the patient's vital signs, particularly hemodynamic parameters, will be conducted throughout the anesthesia period to ensure safety and efficacy.
Study NCT06713174 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Assessment of Interleukin 8 and 10 Level Changes Before and During Root Canal Treatment for Necrotic Pulp with Apical Periodontitis
Description: This study will be performed to investigate interleukin-8 (IL-8) and interleukin-10 (IL-10) level changes in gingival crevicular fluid (GCF) and periapical fluid before and during root canal treatment (RCT) in patients with necrotic pulp and apical periodontitis. The null hypothesis tested will be There is no significant difference in (IL-8) and (IL-10) levels in gingival crevicular fluid (GCF) and periapical before and during root canal treatment (RCT) for necrotic pulp with apical periodontitis.
Study NCT06713109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview techniques
Description: Motivational interviews will be conducted 4 times. As a result of these interviews, the breastfeeding problem or anxiety in the mother will be evaluated and the effectiveness of the interview will be solved.
Study NCT06137469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/SHR20004
Description: SHR20004 was administered by titration, with all subjects starting on Day 4 with an initial dose of 0.03 mg/d of SHR20004 or placebo, with the dose being increased by 0.03 mg/d per week. The dose was increased to 0.15 mg/d and then maintained for 5 days.
Study NCT04821622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talazoparib plus enzalutamide
Description: experimental arm
Study NCT04821622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus enzalutamide
Description: Active comparator arm
Study NCT06137469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Placebo
Description: Placebo was administered by titration, with all subjects starting on Day 4 with an initial dose of 0.03 mg/d of SHR20004 or placebo, with the dose being increased by 0.03 mg/d per week. The dose was increased to 0.15 mg/d and then maintained for 5 days.
Study NCT05316285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga exercise
Description: Yoga lesson practices will be designed and implemented by instructors physiotherapists who have completed 200 hours of yoga instructor training (RYT-200). The yoga program, which will consist of one-hour sessions once a week, is planned to last 14 weeks. 4 weeks of classes will be theoretical lessons related to yoga philosophy, 10 weeks of yoga sessions will be applied every week on different concepts such as upper extremity and / or lower extremity focused strengthening and / or flexibility and breathing exercises. In addition to this training, students will be advised to repeat the practices once a week. Sessions will begin with breathing practices called pranayama, followed by yoga postures called asanas, and the sequence will be finished with savasana pose. In this pose, guided meditations will be performed on subjects such as body awareness and self-compassion.
Study NCT06119399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing Exercise
Description: Diaphragmatic breathing exercise will be taught by placing the subject comfortably positioned with either therapist or the patient's hand directed over the abdominal area and instructing the subjects to focus on an outward movement of the abdominal area throughout inspiration and an inward movement of the abdominal area during expiration. (4 sets, and as each set had 4 complete breathing breaks, these exercises will be conducted for 3 days a week for 6 weeks)
Study NCT06119399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pursed Lip Breathing Exercise
Description: Pursed lip breathing exercises will be performed by necessitating the subjects to inhale through their nose and then exhaling slowly for a period of 4-6 s by pursing the lips
Study NCT06119399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doming of the diaphragm
Description: * The physiotherapist places the thumbs just inferior to the patient's lower costal margin and xiphoid process with the thumbs pointing cephalad.~* The patient is instructed to take a deep breath and exhale. On exhalation, the physiotherapist's thumbs follow the diaphragm, which permits the thumbs to move posteriorly.~* The patient is instructed to inhale, and the physiotherapist gently resists this motion.~* The patient is instructed to exhale, and the physiotherapist gently follows this motion posteriorly and cephalad, as the thumbs are now beneath the costal margin and xiphoid process.~* The patient inhales as the physiotherapist maintains pressure on the upper abdomen and then, on repeated exhalation, encourages further cephalad excursion.~* This procedure is repeated for three to five respiratory cycles until the diaphragm domes easily at the end of exhalation.
Study NCT06711822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockplus-10
Description: Patients with coronary artery calcification who are planned to undergo PCI and are deemed in need of ShockPulse-10 treatment by their physicians
Study NCT06714266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Trilaciclib 240mg/m2, intravenous infusion for 30 minutes, completed within 4 hours before daily chemotherapy; Chemotherapy regimen: FP regimen (cisplatin/carboplatin +5-FU regimen: cisplatin 75mg/m2 D1, D2, D3 or carboplatin AUC 5, intravenous infusion D1; 5-FU 1000 mg/m2, intravenous infusion, D1-4; Q3W); TP regimen (cisplatin/carboplatin +5-FU regimen: cisplatin 75mg/m2 D1, D2, D3 or carboplatin AUC 5, intravenous infusion D1; Docetaxel 75mg/m2 or albumin paclitaxel 200mg, IV infusion, D1, 8; Q3W). The specific dose can be adjusted according to the situation.~Immunotherapy: Pembrolizumab 200mg q2w Targeted therapy: cetuximab (400mg/m2 qw 250mg/m2 qw) Some patients can be treated with maintenance therapy, and the treatment regimen is immunotherapy or targeted therapy combined with Trilaciclib
Study NCT06711900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: IV Infusion
Study NCT06711900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV Infusion
Study NCT06711900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion
Study NCT06711900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: IV Infusion
Study NCT06711900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin or cisplatin
Description: IV Infusion
Study NCT04575883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedBIKE HIIT
Description: Participants will complete a high intensity interval training exercise program 3 times a week for 12 weeks (36 sessions total)
Study NCT06708962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan's mobilization
Description: Mulligan mobilization isthe concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient.
Study NCT06708962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroid injection for rotator cuff tendinopathy
Description: corticosteroid injection for rotator cuff helps resolving inflammation which occur for paraplegic patients from overuse of the crutches